Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinom…

Einleitung: Oncolytic viruses represent a novel therapeutic approach (so called virotherapy) in the treatment of malignant neoplasias, employing their ability to selectively infect, replicate in and (onco-) lyse tumor cells without affecting normal tissues. Nevertheless, in monotherapy virotherapeutics were found to face various limitations in recent clinical trials. To address those limitations, epigenetic compounds, especially histone deacetylase inhibitors (HDACi), seem to be qualified for putative combination strategies (i.e. epi-virotherapeutic) in the field of oncolytic virotherapy. Material und Methoden:…